Content overview: “Trump Administration Advances Plan for Peptide Drugs Favored by RFK Jr.”. health officials are moving forward with a proposal to let specialty pharmacies compound certain peptide drugs, a category of largely unregulated injectables championed by Health Secretary Robert F. The plan, which has not yet been finalized, would expand access to substances like BPC-157 and thymosin alpha-1, which are popular in wellness and anti-aging circles but lack FDA approval for most uses. Supporters say compounding could lower costs and increase availability for patients seeking alternatives to conventional treatments.
Critics warn that without rigorous oversight, patients could be exposed to unsafe or ineffective products. The move reflects the administration's broader push to reduce regulatory barriers for alternative therapies, aligning with Kennedy's long-held skepticism of mainstream medicine. If implemented, it could reshape the peptide market and intensify debate over drug safety and patient autonomy. The full version stays on the original page, which this listing opens directly.